key: cord-0741028-emqhxan9
authors: Zhang, Hui; Charmchi, Zeinab; Seidman, Roberta J; Anziska, Yaacov; Velayudhan, Vinodkumar; Perk, Jonathan
title: COVID‐19 associated myositis with severe proximal and bulbar weakness
date: 2020-06-14
journal: Muscle Nerve
DOI: 10.1002/mus.27003
sha: c91e05a109730c5941408460b81b14afd9c96903
doc_id: 741028
cord_uid: emqhxan9

nan

Coronavirus disease 2019 , caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is known for life-threatening respiratory illnesses, but there is increasing evidence of neurologic manifestations . 1 Here we report a patient with COVID-19 associated inflammatory myopathy, presenting with facial, bulbar and proximal limb weakness.

A 58-year-old woman presented with cough, dyspnea, and myalgia. Vital signs were stable and her physical exam was unremarkable. Initial polymerase chain reaction (PCR) testing for SARS-CoV-2 was negative and the patient was discharged home. She returned three weeks later with more severe dyspnea, cough, dysarthria, dysphagia, odynophagia and severe generalized weakness with inability to ambulate. She had no sensory symptoms or bowel or bladder dysfunction.

Physical examination was significant for tachycardia to 110 beats per minute and oxygen saturation of 88% on room air. She had bilateral ptosis, facial weakness, hypernasal dysarthria and profound symmetric proximal limb weakness. Reflexes were symmetrically diminished. Repeated SARS-CoV-2 PCR was positive.

Magnetic resonance imaging (MRI) of the entire neuroaxis showed no central or peripheral nervous system involvement, but demonstrated diffuse muscle edema and enhancement, with a region of myonecrosis ( Figure 1A and 1B).

Motor nerve conduction studies of the peroneal, tibial, ulnar, and median nerves were unremarkable, as were sensory studies of the ulnar and median nerves; no responses were elicited from the superficial peroneal and sural nerves. Three hz repetitive stimulation of the ulnar nerve pre-and post-1 minute exercise showed no change in the compound muscle action potential amplitude recorded from the abductor digiti minimi muscle during a series of 10 Accepted Article stimuli. Needle electromyography of the right vastus lateralis, iliopsoas, and deltoid muscles revealed sparse fibrillation potentials; no motor units could be activated.

On admission, creatine kinase (CK) was elevated to 700 U/L. Anti-Sjögren's-syndrome-related antigen (anti-SSA) and anti-small ubiquitin-like modifier-1 activating enzyme (anti-SAE 1) antibodies were both strongly positive and Ku antibody was weakly positive. Acetylcholine receptor (AChR) binding, modulating and muscle specific kinase (MuSK) antibodies were all negative ( Table 1) .

Muscle biopsy showed perivascular inflammatory infiltration with endomysial extension, regenerating fibers and upregulation of HLA Class ABC expression on non-necrotic fibers.

Cytochrome oxidase/succinic dehydrogenase enzyme histochemistry were unremarkable.

Vacuolar change and curvilinear bodies (on electron microscopy) suggestive of hydroxychloroquine myopathy were absent ( Figure 1C to 1F).

Our presumptive diagnosis was COVID-19 associated myositis and a five-day course of 1000 mg intravenous methylprednisolone was administered. Elevated interleukin-6 was found and tocilizumab was given. Anticoagulation was administered for left brachial vein thrombosis and a five-day course of hydroxychloroquine and azithromycin were administered as well. Over two weeks, her CK levels normalized and she recovered the ability to raise her arms and legs from the bed. She showed slow improvement in bulbar function and her speech became more intelligible. She did not require mechanical ventilation, however, a percutaneous endoscopic gastrostomy (PEG) tube was inserted to allow for sufficient nutrition.

This article is protected by copyright. All rights reserved. Viral infection is a well-known cause of myositis in which influenza A and B are the most common causes in the united states. 2 Myopathy with elevated CK levels has been reported in patients with severe acute respiratory syndrome (SARS). 3 Limited pathological studies suggested vasculitis or immune-mediated mechanism as the potential cause for myopathy, without evidence of direct viral invasion. 4, 5 Myalgias are reported in up to a half of patients with SARS-CoV-2 infection. Serum CK levels elevations depend on the disease severity, ranging from mild to frank rhabdomyolysis. 1,6,7,8 A recent report described a COVID-19 patient with myalgia, proximal weakness, elevated CK level and muscle edema on MRI. 9

Here we report a COVID-19 patient with associated myositis involving proximal limb, bulbar and facial muscles. The severe immune activation known to occur in COVID-19 patients likely plays a major pathophysiologic role. Myositis and myasthenia gravis (MG) may coexist and although specific antibodies were negative and ulnar repetitive nerve stimulation was normal, the severe bulbar involvement raises the possibility of superimposed MG. This is especially interesting in light of a recent report of patients with MG and COVID 19, one of whom was successfully extubated after treatment with tocilizumab 10 . Direct viral invasion was not detected by electron microscopy. The finding of multiple serologic autoimmune antibodies is intriguing suggesting an epiphenomenon rather than activation or unmasking of a specific immune response directed to the muscles. Further studies are needed to elucidate the mechanisms, appropriate treatment, and long-term clinical outcomes of muscular manifestations associated with COVID- 

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Bacterial, fungal, parasitic, and viral myositis

Neurological manifestations in severe acute respiratory syndrome

The clinical pathology of severe acute respiratory syndrome (SARS): a report from China

Myopathic changes associated with severe acute respiratory syndrome: a postmortem case series

COVID-19 and the nervous system

Weakness and elevated creatinine kinase as the initial presentation of coronavirus disease 2019 (COVID-19)

Rhabdomyolysis as a presentation of 2019 novel coronavirus disease

Anti-melanoma differentiation-associated gene 5 (MDA5), nuclear matrix protein (NXP-2), transcriptional intermediary factor (TIF) GAMMA, Anti PM Scl-100, U2 small nuclear ribonucleoprotein (U2 snRNP), Ku, Anti-Sjögren's-syndrome-related antigen A (Ani SSA) and anti-small ubiquitin-like modifier-1 activating enzyme